AI-Enabled Drug Discovery and Clinical Trials Market Report 2025-2035

The AI-Enabled Drug Discovery and Clinical Trials Market Report 2025-2035: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Accelerated Drug Development Timelines and Cost Efficiency Driving Market Growth

Key drivers propelling the AI-enabled drug discovery and clinical trials market include the ability to reduce drug development timelines, lower research costs, and improve operational efficiency. AI technology streamlines various phases of drug discovery, including target identification, molecule screening, and clinical trial optimization, leading to faster and more cost-effective drug development. Additionally, advancements in AI-driven platforms–such as generative models for molecular design and predictive analytics for patient recruitment–are expected to further boost market growth.

For instance:

• On 24th March 2025, researchers at the Oxford Drug Discovery Institute have employed AI-powered databases to accelerate Alzheimer's drug discovery. By efficiently analyzing extensive biomedical data, they identified 54 immune system-related genes for potential testing, significantly reducing the time required for gene evaluation and expediting the identification of promising drug targets.
• On 21st March 2025, AstraZeneca announced a $2.5 billion investment over five years to establish a research and manufacturing center in Beijing, featuring an AI and data science laboratory. This initiative underscores the company's commitment to leveraging AI for enhancing early-stage research and clinical development, aiming to expedite drug discovery and reduce associated costs.
• On 8th January 2025, Advanced Micro Devices Inc. (AMD) invested $20 million in Absci Corp to enhance AI-backed drug discovery efforts. This collaboration aims to expedite biologics innovation and reduce costs by leveraging AMD's advanced computing capabilities, highlighting the growing role of AI in transforming traditional drug development processes.

However, some large pharmaceutical companies remain hesitant to fully adopt AI-driven outsourcing due to concerns about data privacy, intellectual property loss, and reduced strategic control. Despite these concerns, the increasing complexity of drug development, combined with the rising costs of in-house operations, is pushing many companies to collaborate with AI solution providers to enhance efficiency and innovation. Emerging economies are also playing a critical role, as pharmaceutical firms seek to capitalize on lower operational costs and advanced AI technologies in these regions.

Regulatory and Data Integration Challenges to Hamper Market Growth

While the adoption of AI offers significant benefits, challenges around regulatory compliance, data integration, and standardization may slow market growth. Strict regulations governing drug approval and patient data protection require AI systems to maintain transparency and explainability, adding layers of complexity to implementation. Additionally, the need for harmonized data across diverse systems and geographies poses a logistical challenge for AI-enabled platforms.

Ensuring real-time collaboration between AI platforms and clinical trial sites also requires robust data infrastructure and seamless integration. For instance, personalized medicine and rare disease trials require advanced AI models capable of managing vast datasets while adhering to stringent regulatory frameworks. As AI adoption grows, industry stakeholders must navigate these administrative and technical challenges to fully realize the potential of AI in drug discovery and clinical trials.

What Questions Should You Ask before Buying a Market Research Report?

• How is the AI-enabled drug discovery and clinical trials market evolving?
• What is driving and restraining the AI-enabled drug discovery and clinical trials market?
• How will each AI-enabled drug discovery and clinical trials submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
• How will the market shares for each AI-enabled drug discovery and clinical trials submarket develop from 2025 to 2035?
• What will be the main driver for the overall market from 2025 to 2035?
• Will leading AI-enabled drug discovery and clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
• Who are the leading players and what are their prospects over the forecast period?
• What are the AI-enabled drug discovery and clinical trials projects for these leading companies?
• How will the industry evolve during the period between 2025 and 2035? What are the implications of AI-enabled drug discovery and clinical trials projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the AI-enabled drug discovery and clinical trials market?
• Where is the AI-enabled drug discovery and clinical trials market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the AI-Enabled Drug Discovery and Clinical Trials market today, and over the next 10 years:

• Our 285-page report provides 107 tables and 155 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2035 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising AI-Enabled Drug Discovery and Clinical Trials prices and recent developments.

Segments Covered in the Report

Component

• Services
• Software Solutions

Application

• Clinical Trials
• Drug Design
• Data Aggregation and Analysis
• Drug Characterisation
• Biomarker Research
• Others

Therapeutic Area

• Oncology
• Cardiovascular Diseases
• Infectious Diseases
• Neurodegenerative Diseases
• Metabolic Diseases
• Immunological Disorders
• Others

End-users

• Pharmaceutical & Biopharmaceutical Companies
• Contract Research Organisations (CROs)
• Academic Institutes and Research Centre

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Spain
• Russia
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Colombia
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the AI-Enabled Drug Discovery and Clinical Trials Market, 2025 to 2035, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

• AiCure
• Aitia
• Atomwise Inc.
• BenevolentAI
• Insilico Medicine
• PathAI, Inc.
• Recursion
• Saama Technologies
• Schr√∂dinger, Inc.
• Tempus
• Unlearn.ai, Inc.

Overall world revenue for AI-Enabled Drug Discovery and Clinical Trials Market, 2025 to 2035 in terms of value the market will surpass US$3,000 million in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the AI-Enabled Drug Discovery and Clinical Trials Market, 2025 to 2035 report help you?

In summary, our 280+ page report provides you with the following knowledge:

• Revenue forecasts to 2035 for AI-Enabled Drug Discovery and Clinical Trials Market, 2025 to 2035, with forecasts for component, application, therapeutic area, and end-users each forecast at a global and regional level – discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2035 for five regional and 24 key national markets – See forecasts for the AI-Enabled Drug Discovery and Clinical Trials Market, 2025 to 2035 in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 11 of the major companies involved in the AI-Enabled Drug Discovery and Clinical Trials Market, 2025 to 2035.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.